Member Info for DinoMustafic

Thanks for that input.

It says no short term financial benefits. Actually it says, not "significant" http://www.pharmaceuticaldaily.com/beximco-pharma-in-jv-with-malaysia-based-biocare-manufacturing/

Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion http://www.pharmaceuticaldaily.com/novartis-2016-full-year-net-income-down-6/

They said they could have less debt if some money was valued like in june. Revenues are double, but they don't say what's the net profit/loss. Only that they managed to reduced debt. http://www.pharmaceuticaldaily.com/alliance-pharma-reduces-net-debt-doubles-revenue/

Atlas Genetics has raised a series D equity issue of £28.4m Consort’s equity share in Atlas Genetics following the raise will be 15.2% http://www.pharmaceuticaldaily.com/consort-in-equity-raise-by-atlas-genetics/

http://www.pharmaceuticaldaily.com/avacta-expects-to-license-affimer-technology-in-2017/ “We start 2017 with great enthusiasm,”CEO says

http://www.pharmaceuticaldaily.com/abzena-nets-300-million-for-its-thiobridge-technology/ I don't understand, they sold it or rent it? also, who's the buyer? what royalties? how much more money "over 300"

It is like in a movie where you want this guy to lose in the end. By the way, this is off topic, and I'm sorry. Just expressing my feelings.

EC’s approval for Sanofi’s Suliqua triggers $10 million payment to Zealand Pharma http://www.pharmaceuticaldaily.com/ecs-approval-for-sanofis-suliqua-triggers-usd-10-million-payment-to-zealand-pharma/

http://www.pharmaceuticaldaily.com/two-directors-resign-one-replacement-for-several-committee-spots/ two resignations from the board, but previously had announced start of two clinical trials, which were kicked off earlier in January. Could they be just late with certain announcements?

Mereo’s CFO will be Diurnal's financial boss. Who's winning here?What does that mean for Mereo, what it means for Diurnal? http://www.pharmaceuticaldaily.com/mereos-coo-and-cfo-richard-bugay-joins-diurnal-as-cfo-uk-drugmakers-shuffle-managers/

In connection to the news from 3 days ago: http://www.pharmaceuticaldaily.com/joseph-gunnar-buys-additional-122500-akers-biosciences-common-shares/

Omega shared an update on the sale. it said: Initially sales will be relatively modest... http://www.pharmaceuticaldaily.com/update-omega-starts-selling-malaria-tests-in-india/ And it said: demand for Malaria tests was expected to increase by 100m to approximately 380m tests in 2016.

It says here: “Omega Visitect Malaria kits are ready for shipment.” How much of those do they sell. Shelf-life 24 months... http://www.pharmaceuticaldaily.com/omega-starts-selling-malaria-tests-in-india/

It's malaria, it's India...

Good point. The size of Stada and the fact that the deal will run for at least 11 years, they are - I am sure - confident it should perform well in the market.

In interim report and accounts for the period ended June 30, 2016, the company said that it expects its topical treatment should be the first choice for doctors in the initial treatment of pain and therefore represents a substantial opportunity in a market with global sales estimated at $2.9 billion. But this is for the UK only... so http://www.pharmaceuticaldaily.com/futura-medical-nets-licensing-deal-with-stada-for-its-pain-relief-gel/

what's with this $22 Million in a quarter? https://pharmaceuticaldaily.com/2016/12/05/amryt-will-sell-aegerions-lojuxta-drug-in-eu-and-further/ sales only?

$22 million in a quarter https://pharmaceuticaldaily.com/2016/12/05/amryt-will-sell-aegerions-lojuxta-drug-in-eu-and-further/

https://pharmaceuticaldaily.com/2016/12/05/amryt-will-sell-aegerions-lojuxta-drug-in-eu-and-further/